https://www.ig.com/se/aktier/marknader-aktier/iovance-biotherapeutics-inc
Handla Iovance Biotherapeutics Inc Aktier | Iovance Biotherapeutics Inc Aktiekurs | Iovance...
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor... [SE]
iovance biotherapeuticshandlaincaktieraktiekurs
https://www.insidermonkey.com/blog/iovance-biotherapeutics-inc-nasdaqiova-q4-2023-earnings-call-transcript-1267390/
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript - Insider Monkey
Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.45 EPS, expectations were $-0.44. Iovance Biotherapeutics, Inc.
earnings call transcriptiovance biotherapeuticsq4 2023
https://www.biospace.com/iovance-biotherapeutics-to-present-at-upcoming-march-2024-conferences
Iovance Biotherapeutics to Present at Upcoming March 2024 Conferences - BioSpace
Mar 4, 2024 - Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte...
iovance biotherapeuticsmarch 2024presentupcomingconferences
https://www.fool.com/investing/2020/01/13/why-iovance-biotherapeutics-shares-dropped-118-tod.aspx
Why Iovance Biotherapeutics Shares Dropped 11.8% Today | The Motley Fool
Jan 13, 2020 - The company announced a string of deals over the weekend that failed to spark investors' optimism.
iovance biotherapeutics11 8sharesdropped
https://www.fool.com/investing/2021/07/08/why-iovance-biotherapeutics-soared-40-in-june/
Why Iovance Biotherapeutics Soared 40% In June | The Motley Fool
Jul 8, 2021 - The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.
iovance biotherapeuticssoared40junemotley
https://investingnews.com/company-news/ovance-biotherapeutics-pricing-public-offering-approximately-220-million-common-stock/
Iovance Biotherapeutics Announces Pricing of Its Public Offering of Approximately $220 Million of...
Jan 4, 2026 - Iovance Biotherapeutics (Nasdaq:IOVA) a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology,...
iovance biotherapeuticspublic offeringannouncespricing
https://www.macrotrends.net/stocks/charts/IOVA/iovance-biotherapeutics/eps-earnings-per-share-diluted
Iovance Biotherapeutics EPS - Earnings per Share 2012-2026 | IOVA | MacroTrends
Iovance Biotherapeutics eps - earnings per share from 2012 to 2026. Eps - earnings per share can be defined as a company's net earnings or losses attributable...
earnings per shareiovance biotherapeuticseps20122026
https://www.financialcontent.com/article/gnwcq-2026-5-7-iovance-biotherapeutics-highlights-positive-first-quarter-2026-results-business-achievements-and-corporate-updates
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and...
1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth
first quarter 2026iovance biotherapeuticshighlightspositive
https://www.einpresswire.com/article/645727020/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 21, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating
iovance biotherapeutics
https://www.biospace.com/iovance-biotherapeutics-to-present-at-upcoming-healthcare-conferences-jan-19-2021
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - Jan 19, 2021 - BioSpace
Jan 20, 2021 - Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans...
jan 19 2021iovance biotherapeutics
https://www.fool.com/investing/2024/04/17/is-iovance-biotherapeutics-stock-a-buy-now/
Is Iovance Biotherapeutics Stock a Buy Now? | The Motley Fool
Apr 17, 2024 - Let's find out if this biotech can keep up its recent momentum.
iovance biotherapeuticsbuy nowstockmotleyfool
https://informaconnect.com/cell-therapy-bioprocessing/speakers/arvind-natarajan/
Arvind Natarajan - Iovance Biotherapeutics | Cell & Gene Therapy International Speaker
iovance biotherapeuticsgene therapyarvindnatarajancell
https://finviz.com/quote?t=IOVA&ta=1&p=d&ty=ea
IOVA - Iovance Biotherapeutics Inc Earnings
IOVA - Iovance Biotherapeutics Inc - Stock screener for investors and traders, financial visualizations.
iovance biotherapeuticsincearnings
https://www.nasdaq.com/market-activity/stocks/iova/analyst-research
Iovance Biotherapeutics, Inc. Common Stock (IOVA) Analyst Research | Nasdaq
Find the latest analyst research, reports, and ratings for Iovance Biotherapeutics, Inc. Common Stock (IOVA) at Nasdaq.com.
iovance biotherapeuticscommon stockanalyst researchincnasdaq
https://melanoma.org/news-press/iovance-biotherapeutics-initiates-biologics-license-application-bla-submission-for-lifileucel-in-advanced-melanoma/
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in...
biologics license applicationiovance biotherapeuticsinitiates
https://www.entrepreneur.com/finance/iovance-biotherapeutics-spikes-on-melanoma-bla-fda/453177
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Oct 8, 2025 - Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
iovance biotherapeuticsspikesmelanomablafda
https://www.fool.com/investing/2025/07/30/iovance-biotherapeutics-stock-due-for-big-rally/
Is Iovance Biotherapeutics Stock Due for a Big Rally? | The Motley Fool
Jul 30, 2025 - The biotech stock has been picking up steam of late -- but will it last?
iovance biotherapeutics
https://finviz.com/quote?t=IOVA&ty=fc
IOVA - Iovance Biotherapeutics Inc Forecast, Target Price
IOVA - Iovance Biotherapeutics Inc - Stock screener for investors and traders, financial visualizations.
iovance biotherapeuticsincforecasttargetprice
https://www.benzinga.com/quote/IOVA/news
Latest Iovance Biotherapeutics Stock News | NASDAQ:IOVA | Benzinga
Get the latest news on Iovance Biotherapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on IOVA performance
iovance biotherapeuticsstock newslatestnasdaqbenzinga
https://www.biospace.com/iovance-biotherapeutics-to-present-at-upcoming-conferences-june-01-2021
Iovance Biotherapeutics to Present at Upcoming Conferences - June 01, 2021 - BioSpace
Jun 2, 2021 - Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans...
iovance biotherapeuticsupcoming conferencesjune 01present
https://www.fool.com/earnings/call-transcripts/2020/02/26/iovance-biotherapeutics-inc-iova-q4-2019-earnings.aspx
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call Transcript | The Motley Fool
Feb 26, 2020 - IOVA earnings call for the period ending December 31, 2019.
earnings call transcriptiovance biotherapeuticsq4 2019
https://www.prnewswire.com/news-releases/iovance-biotherapeutics-expands-partnership-with-wuxi-advanced-therapies-business-300859740.html
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
/PRNewswire/ -- Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte...
iovance biotherapeuticsadvanced therapiesexpandspartnershipwuxi
https://www.benzinga.com/news/small-cap/23/03/31516381/why-iovance-biotherapeutics-shares-are-trading-higher-today
Why Iovance Biotherapeutics Shares Are Trading Higher Today - Iovance Biotherapeutics (NASDAQ:IOVA)...
Mar 27, 2023 - Iovance Biotherapeutics (NASDAQ: IOVA) shares are trading higher on Monday after the company completed its Biologics License Application submission for...
iovance biotherapeuticssharestradinghighertoday
https://www.biospace.com/employer/400593/iovance-biotherapeutics-inc
Iovance Biotherapeutics, Inc. - BioSpace
iovance biotherapeuticsinc
https://www.biospace.com/iovance-biotherapeutics-to-present-clinical-data-for-tumor-infiltrating-lymphocyte-til-therapy-at-iaslc-2023-world-conference-on-lung-cancer
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at...
Jul 26, 2023 - Iovance Biotherapeutics, Inc. announced oral and poster presentations reporting clinical and preclinical data for tumor infiltrating lymphocyte therapies at...
tumor infiltrating lymphocyte
https://www.einpresswire.com/article/646371007/iovance-biotherapeutics-to-present-clinical-data-for-tumor-infiltrating-lymphocyte-til-therapy-at-iaslc-2023-world-conference-on-lung-cancer
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at...
Jul 25, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating
tumor infiltrating lymphocyte
https://www.biospace.com/press-releases/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - BioSpace
https://www.benzinga.com/news/23/12/36401053/iovance-biotherapeutics-nio-netease-and-other-big-stocks-moving-lower-on-wednesday
Iovance Biotherapeutics, Nio, NetEase And Other Big Stocks Moving Lower On Wednesday - Cheche Group...
Dec 27, 2023 - U.S. stocks traded mostly higher, with the Dow Jones index gaining around 80 points on Wednesday.
https://menafn.com/1109652035/IOVA-Shareholders-Have-The-Right-To-Lead-The-Iovance-Biotherapeutics-Inc-Securities-Lawsuit-Contact-The-DJS-Law-Group-To-Discuss-Your-Rights-ELV
IOVA Shareholders Have The Right To Lead The Iovance Biotherapeutics, Inc. Securities Lawsuit -...
IOVA Shareholders Have The Right To Lead The Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact The DJS Law Group To Discuss Your Rights - ELV. LOS...
the right
https://menafn.com/1109649209/IOVA-INVESTOR-NEWS-Iovance-Biotherapeutics-Inc-Has-Been-Sued-For-Securities-Fraud-Contact-BFA-Law-Before-July-14-Deadline-NASDAQIOVA
IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. Has Been Sued For Securities Fraud Contact BFA...
IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. Has Been Sued For Securities Fraud Contact BFA Law Before July 14 Deadline (NASDAQ:IOVA). NEW YORK, June 08,...
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovance-biotherapeutics-inc-nasdaqiova-shares-fly-26-but-inv
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth -...
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shareholders are no doubt pleased to see that the share price has bounced...
https://menafn.com/1109652409/The-Gross-Law-Firm-Notifies-Iovance-Biotherapeutics-Inc-Investors-Of-A-Class-Action-Lawsuit-And-Upcoming-Deadline-IOVA
The Gross Law Firm Notifies Iovance Biotherapeutics, Inc. Investors Of A Class Action Lawsuit And...
The Gross Law Firm Notifies Iovance Biotherapeutics, Inc. Investors Of A Class Action Lawsuit And Upcoming Deadline IOVA. NEW YORK, June 09, 2025 (GLOBE...
https://www.iovance.com/
Investigating TIL Therapy for Cancer - Iovance Biotherapeutics
Learn about our investigational tumor infiltrating lymphocyte (TIL) therapy. View our clinical trials and pipeline.
til therapyinvestigatingcanceriovancebiotherapeutics
https://www.biospace.com/iovance-biotherapeutics-to-host-fourth-quarter-and-full-year-2023-financial-results-conference-call-and-webcast-on-wednesday-february-28-2024
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call...
Feb 23, 2024 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...
https://www.tilcelltherapy.com/
TIL Therapy Clinical Trials | Iovance Biotherapeutics
May 28, 2025 - Learn about our clinical studies in advanced melanoma, non-small cell lung cancer, gynecologic cancer and other cancers. Call us to get started.
til therapyclinical trialsiovancebiotherapeutics